Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
Dr. Bill Morice shares how clinical diagnostics are expanding to guide treatment and enable clinicians to target therapies more precisely.
In this episode of Lab Medicine Rounds, Dr. Daniela Hermelin, an Assistant Professor of Pathology at Saint Louis University School of Medicine and Medical Director of Transfusion Medicine Services at SSM Health St. Louis University Hospital and Cardinal Glennon Children's Hospital, discusses what learners should pay attention to during training to be successful in real life.
In this episode, Dr. Morice and Dr. Pritt talk about what the recent surge in COVID-19 cases means and how we can all do our part to help prevent further spread.
The discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.
For the last year, Emily Fernholz’s time has been consumed by COVID-19. But as the pandemic has eased, she’s turned her attention back to the usual business of Mayo’s Clinical Virology/Parasitology Laboratory: testing for virus-, parasite-, and vector-borne diseases.
Elitza Theel, Ph.D., director of Mayo Clinic’s Infectious Disease Serology Lab was featured in a discussion on NBC News about COVID-19 antibody tests.
This week's research roundup features a study on the prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma.
Top highlights include: Changes to outpatient visitor restrictions in Rochester, MN, Mayo Clinic Q&A podcast on the COVID-19 delta variant, and respiratory illnesses on the rise with symptoms similar to COVID-19.
Top highlights include: a third dose of COVID-19 vaccine sparking debate over booster shots, rare reactions with the J&J COVID-19 vaccine, and can vaccinated people get long Covid.
In this episode, Dr. Morice and Dr. Pritt, discuss the rise in cases of COVID-19 caused by the coronavirus delta variant in the U.S., especially in areas with low vaccination rates.
In May and June 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
This week’s research roundup features a study on acute treatments for episodic migraine in adults: A systematic review and meta-analysis.